Texas Digestive Disease Consultants - San Marcos | ClinicalTrials HQ

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis	Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease	Active, not recruiting	Phase 3	2026-06-01		NCT03900429
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)	Digestive System Diseases, Dyslipidemias, Fibrosis, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, endocrine system disorder, fatty liver disease, hyperlipidemia, hyperthyroxinemia, liver disorder, metabolic disease, metabolic dysfunction-associated steatotic liver disease, thyroid gland disorder, thyroid hormone resistance syndrome	Active, not recruiting	Phase 3	2026-05-27		NCT04951219
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk	Blood-Borne Infections, DNA Virus Infections, Digestive System Diseases, Digestive System Neoplasms, Fibrosis, Hepadnaviridae infectious disease, Infections, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, adenocarcinoma, carcinoma, cirrhosis of liver, epithelial neoplasm, hepatitis, hepatitis B virus infection, hepatocellular carcinoma, infectious disease, liver cancer, liver disorder, neoplasm, viral hepatitis, viral infectious disease	Active, not recruiting	Not stated	2025-10-15		NCT05064553